Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative intraperitoneal irinotecan with adjuvant hyperthermia in advanced gastric cancer
2024-516042-18-00Phase 3Completed
- Sponsor
- Jagiellonian University Medical College
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in gastric adenocarcinoma comparing Intraperitoneal irinotecan + hyperthermic adjunctive therapy with Standard of care without intraperitoneal irinotecan (2 arms). Primary endpoints: Peritoneal recurrence rate, Recurrence rates and 1 more. Started Sep 2024; status: completed.
02
Drugs
irinotecan
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on 2024-516042-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516042-18-00.